Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maddalena Donini

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Oncology Reviews|May 21, 2015
Systemic adjuvant therapies in renal cell carcinomaSebastiano Buti, Melissa Bersanelli, Maddalena Donini, et al.
Acta Bio-Medica : Atenei Parmensis|February 12, 2013
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysisSebastiano Buti, Maddalena Donini, Silvia Lazzarelli, et al.
Lung Cancer (Amsterdam, Netherlands)|February 5, 2013
When a thymic carcinoma "becomes" a GISTValentina Rossi, Maddalena Donini, Pietro Sergio, et al.
Drugs in R&D|September 13, 2017
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective StudySebastiano Buti, Maddalena Donini, Melissa Bersanelli, et al.
Drugs in R&D|May 30, 2018
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective StudySebastiano Buti, Maddalena Donini, Melissa Bersanelli, et al.
Tumori|April 13, 2012
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinomaSebastiano Buti, Rodrigo Kraft Rovere, Maddalena Donini, et al.
Expert Review of Anticancer Therapy|June 2, 2020
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directionsMaddalena Donini, Sebastiano Buti, Francesco Massari, et al.
Expert Review of Anticancer Therapy|February 11, 2025
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated reviewGiulia Claire Giudice, Michele Maffezzoli, Irene Testi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 29, 2010
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) studySebastiano Buti, Silvia Lazzarelli, Matteo Dalla Chiesa, et al.
Future Oncology (London, England)|March 20, 2019
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancerOrazio Caffo, Gaetano Facchini, Elisa Biasco, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Oncology Reviews|May 21, 2015
Systemic adjuvant therapies in renal cell carcinomaSebastiano Buti, Melissa Bersanelli, Maddalena Donini, et al.
Acta Bio-Medica : Atenei Parmensis|February 12, 2013
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysisSebastiano Buti, Maddalena Donini, Silvia Lazzarelli, et al.
Lung Cancer (Amsterdam, Netherlands)|February 5, 2013
When a thymic carcinoma "becomes" a GISTValentina Rossi, Maddalena Donini, Pietro Sergio, et al.
Drugs in R&D|September 13, 2017
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective StudySebastiano Buti, Maddalena Donini, Melissa Bersanelli, et al.
Drugs in R&D|May 30, 2018
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective StudySebastiano Buti, Maddalena Donini, Melissa Bersanelli, et al.
Tumori|April 13, 2012
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinomaSebastiano Buti, Rodrigo Kraft Rovere, Maddalena Donini, et al.
Expert Review of Anticancer Therapy|June 2, 2020
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directionsMaddalena Donini, Sebastiano Buti, Francesco Massari, et al.
Expert Review of Anticancer Therapy|February 11, 2025
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated reviewGiulia Claire Giudice, Michele Maffezzoli, Irene Testi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 29, 2010
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) studySebastiano Buti, Silvia Lazzarelli, Matteo Dalla Chiesa, et al.
Future Oncology (London, England)|March 20, 2019
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancerOrazio Caffo, Gaetano Facchini, Elisa Biasco, et al.
Pageof 2